Repertoire Immune Medicines Nachrichten und Aktivitäten

Siehe das Organigramm mit seine 17 wichtigsten Führungskräfte

Die meist gesuchten Biographien bei Repertoire Immune Medicines

• Torben Nissen, Chief Executive Officer
• Doug Cole, Director
• JC Gutierrez-Ramos, Director

Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Repertoire Immune Medicines nachzuverfolgen.

Repertoire Immune Medicines hat 2.435 Konkurrenten , einschließlich Vertex Pharmaceuticals (USA), Lonza (Schweiz) und Eurofins (Luxemburg).

Popular M&A news in Biotechnologie

• Crystalys Therapeutic hat gerade eine Spendenaktion von 130 Millionen Dollar angekündigt. (veröffentlicht am 23, Juli 2026).
• Ipsen hat Memo Therapeutics erworben (veröffentlicht am 22, Juli 2026).
• AdvanCell hat gerade eine Spendenaktion von 315 Millionen Dollar angekündigt. (veröffentlicht am 21, Juli 2026).

Andere vorgeschlagene Kontakte der Biotechnologie branche

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer bei Inceptive
• Jan Van de Winkel - President and Chief Executive Officer bei Genmab
• Robert Gould - Board Member bei Fulcrum Therapeutics

Mehr über die Biotechnologie branche erfahren

Neueste Pressemitteilungen nach Repertoire Immune Medicines

• Repertoire® Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201 • Repertoire Immune Medicines
• Repertoire® Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors • Repertoire Immune Medicines
• Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases • Repertoire Immune Medicines
• Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer • Repertoire Immune Medicines
• Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic • Repertoire Immune Medicines
• Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease • Repertoire Immune Medicines
• Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • Repertoire Immune Medicines
• Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics • Repertoire Immune Medicines
• Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer • Repertoire Immune Medicines
• New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer • Repertoire Immune Medicines
• View more press releases Close

Social media about Repertoire Immune Medicines

• Repertoire Immune Medicines auf Wikipedia, Google News & Yahoo Finance
• Repertoire Immune Medicines auf LinkedIn, X (Twitter) & YouTube